BMO lifts Protagonist Therapeutics price target to $190
BMO Capital raised its Protagonist Therapeutics price target to $190.00 per share from $178.00 and maintained an Outperform rating, per Benzinga/TradingView.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.